BioSpace News Archive

Biotech Bay

Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients

Edwards Lifesciences Corporation announced new data demonstrating early and sustained health status advantages for severe aortic stenosis patients at low surgical risk treated with the Edwards SAPIEN 3 valve.

September 29, 2019
·
4 min read
Drug Development

Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites

Clover Biopharmaceuticals announced that the first patient was dosed in another Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in China for the treatment of cancer patients with malignant ascites.

September 29, 2019
·
4 min read
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study

Verzenio plus fulvestrant significantly extended life to a median of 46.7 months vs. 37.3 months compared to fulvestrant alone - MONARCH 2 showed statistically significant results for women whose disease progressed following endocrine therapy

September 29, 2019
·
23 min read
Drug Development

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

Interim Results from Pivotal Neoadjuvant/Adjuvant Phase 3 KEYNOTE-522 Trial Presented for the First Time at ESMO 2019 Congress During Presidential Symposium

September 29, 2019
·
34 min read
Drug Development

Isofol Announces Presentation on the Global Phase 3 Study of Arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress

Isofol Medical AB, announced a poster presentation on the ongoing global Phase 3 AGENT clinical study in patients with metastatic colorectal cancer.

September 29, 2019
·
3 min read